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Background: The incidence and risk factors of central nervous system (CNS) involvement in peripheral T-cell
lymphomas (PTCLs) are still unclear.
Patients and methods: We analyzed 228 patients with PTCLs, excluding cases of extranodal natural killer/T-cell
lymphoma and primary cutaneous T-cell lymphoma, by retrospectively collecting the clinical features and outcomes of
the patients.
Results: Twenty events (8.77%, 20/228) of CNS involvement were observed during a median follow-up period of
13.9 months (range 0.03–159.43). Based on univariate analysis, elevated serum lactate dehydrogenase (LDH) level
[P = 0.019, relative risk (RR) 5.904, 95% conﬁdence interval (CI) 1.334–26.123] and involvement of the paranasal sinus
(P = 0.032, RR 3.137, 95% CI 1.105–8.908) adversely affect CNS involvement. In multivariate analysis, both were
independently poor prognostic factors for CNS relapse [elevated LDH level: P = 0.011, hazard ratio (HR) 6.716, 95% CI
1.548–29.131; involvement of the paranasal sinus: P = 0.008, HR 3.784, 95% CI 1.420–10.083]. The survival duration
of patients with CNS involvement was signiﬁcantly shorter than that of the patients without CNS involvement (P =
0.009), with median overall survival of 7.60 months (95% CI of 4.92–10.28) versus 27.43 months (95% CI of 0.00–
57.38), respectively.
Conclusions: Elevated LDH level and involvement of the paranasal sinus are two risk factors for CNS involvement in
patients with PTCLs. Considering the poor prognoses after CNS relapse, prophylaxis should be considered with the
presence of any risk factor.
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introduction
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous
group of malignancies derived from mature or post-thymic T
cells and natural killer (NK) cells, representing 12% of all
non-Hodgkin lymphomas (NHL) in Western countries [1].
However, in the Asian population, the incidence of the disease
is known to be higher [2, 3]. Because of its rare incidence and
the lack of standardized treatment strategies, the prognosis of
the disease is worse than that of B-cell lymphomas and the
natural course is not well-understood.
Many authors have reported the risk factors and the
prognostic value of involvement of the central nervous system
(CNS) in patients with B-cell lymphoma [4–6]. Patients with
aggressive lymphomas such as lymphoblastic and Burkitt’s
lymphoma are at high risk for CNS involvement (30–50%), and
routine CNS prophylaxis for these diseases is recommended. In
aggressive NHLs, involved sites, including testis [7], paranasal
sinus [8], breast [9] and bone marrow [10], are also known to
affect the incidence of CNS involvement. Other clinical factors
including the presence of B symptoms, high lactate
dehydrogenase (LDH), two or more extranodal involvements,
advanced stage, low albumin level and young age are reported
to have an adverse inﬂuence on CNS involvement [4]. The
prognoses of patients with CNS disease are dismal, with
a median survival of 2–6 months, which is even shorter than
that of patients with non-CNS relapse [11].
With respect to PTCLs, few studies have reported on the
incidence of CNS involvement [12, 13] and no study has
suggested speciﬁc risk factors for CNS involvement in the
disease. This lack of information may be attributed to the low
incidence and various subtypes of PTCLs. However, as novel
treatment strategies enable patients with PTCLs to survive
o
r
i
g
i
n
a
l
a
r
t
i
c
l
e
*Correspondence to: Dr W. S. Kim, Division of Hematology–Oncology, Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50
Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. Tel: +822-3410-6548;
Fax: +822-3410-1757; E-mail: wskimsmc@skku.edu
Both authors contributed equally as senior authors.
ª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.longer, cases of CNS involvement may also be increasing in
frequency. Therefore, identiﬁcation of risk factors for CNS
involvement in patients with PTCLs is necessary.
Recently, Kim et al. reported that the incidence of CNS
involvement in extranodal NK/T-cell lymphoma was 5.76%
and suggested that a high NK/T-cell lymphoma prognostic
index (NKPI) score [14] could be a predictive factor [15, 16].
However NK/T cell lymphoma differs from other PTCLs in
that it frequently originates from the oronasal or aerodigestive
areas.
Figure 1. Patient cohort [*other T-cell neoplasms include other T-cell leukemias, natural killer (NK) cell leukemia, lymphoblastic lymphoma, extranodal
NK/T-cell lymphoma, primary cutaneous peripheral T-cell lymphomas, mycosis fungoides, Sezary syndrome and chronic lymphoproliferative disordero f
NK cells; **PTCL-NOS, peripheral T-cell lymphoma, not otherwise speciﬁed; AITL, angioimmunoblastic T-cell lymphoma; HSTL, hepatosplenic T-cell
lymphoma; EATL, enteropathy-associated T-cell lymphoma; ALCL, anaplastic large cell lymphoma; Kim et al. 20].
Table 1. Clinical parameters according to histologic subtype
Histologic subtypes PTCL-NOS (%) ALCL (%) AITL (%) HSTL (%) EATL (%) Total (%)
Number of cases 130 32 52 6 8 228
Demographics
Sex
Male 86 (66.2) 20 (62.5) 32 (61.5) 1 (16.7) 4 (50) 143 (62.7)
Female 44 (33.8) 12 (37.5) 20 (38.5) 5 (83.3) 4 (50) 85 (37.3)
Age, median (years) 52.5 36.5 58.5 36.5 51.5 53
£50 59 (45.4) 24 (75.0) 9 (17.3) 5 (83.3) 4 (50.0) 101 (44.3)
>50 71 (54.6) 8 (25.0) 43 (82.7) 1 (16.7) 4 (50.0) 127 (55.7)
Clinical features
ECOG PS ‡ 2 34 (26.2) 8 (25.0) 21 (40.4) 3 (50.0) 3 (37.5) 69 (30.3)
B symptom present 68 (52.3) 18 (56.3) 34 (65.4) 3 (50.0) 3 (37.5) 125 (55.8)
Serum LDH > UNL 81 (62.3) 14 (43.8) 42 (80.8) 2 (40.0) 4 (50.0) 143 (62.7)
Extranodal involvement > 1 33 (25.4) 18 (56.3) 26 (50.0) 5 (83.3) 4 (50.0) 86 (37.7)
Bone marrow involvement 42 (32.6) 12 (38.7) 28 (53.8) 5 (83.3) 0 (0.0) 87 (38.2)
Paranasal sinus involvement 22 (16.9) 4 (13.3) 5 (9.6) 0 (0.0) 0 (0.0) 31 (13.6)
Ann Arbour stage
I/II 36 (27.7) 10 (31.3) 2 (3.8) 0 (0.0) 1 (12.5) 49 (21.5)
III/IV 94 (72.3) 22 (68.8) 50 (96.2) 6 (100) 7 (87.5) 179 (78.5)
First-line treatment
CHOP/CHOP-like regimen 114 (87.6) 27 (84.4) 50 (96.2) 5 (83.3) 8 (100) 204 (89.5)
Regimen other than CHOP 8 (6.2) 4 (12.5) 1 (1.9) 1 (16.7) 0 (0) 14 (6.1)
No treatment 8 (6.2) 1 (3.1) 1 (1.9) 0 (0) 0 (0) 10 (4.4)
Prognostic index
IPI risk
Low/low intermediate 86 (66.2) 19 (59.4) 15 (28.8) 3 (50.0) 5 (62.5) 128 (56.1)
High/high intermediate 44 (33.8) 13 (40.6) 37 (71.2) 3 (50.0) 3 (37.5) 100 (43.9)
PIT group
1/2 71 (54.6) 20 (62.5) 13 (25.0) 3 (50.0) 5 (62.5) 112 (49.1)
3/4 59 (45.4) 12 (37.5) 39 (75.0) 3 (50.0) 3 (37.5) 116 (50.9)
PTCL-NOS, peripheral T-cell lymphoma, not otherwise speciﬁed; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma;
HSTL, hepatosplenic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; PS, performance
status; LDH, lactate dehydrogenase; UNL, upper normal limit; CHOP, combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and
prednisone; IPI, international prognostic index; PIT, prognostic index for PTCL-NOS.
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clinical features, predictive factors and prognostic role of CNS
involvement in patients with PTCLs.
patients and methods
patients
Patients older than 15 years who were diagnosed with mature T-cell
lymphoma from June 1995 to August 2009 were included in the analysis.
Based on the World Health Organization classiﬁcation for mature T-cell
neoplasms, we included patients with PTCL, not otherwise speciﬁed (NOS),
anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell
lymphoma (AITL), hepatosplenic T-cell lymphoma (HSTL) and
enteropathy-associated T-cell lymphoma (EATL). All of the pathologic
diagnoses were based on hematoxylin and eosin staining, and
immunostaining for antigens such as CD3, CD4, CD30 and CD56. If
needed, further analysis for T-cell receptor class or Epstein–Barr virus in
situ hybridization can be carried out.
The following subtypes were excluded: T-cell leukemias, NK cell
leukemia, lymphoblastic lymphoma, extranodal NK/T-cell lymphoma,
primary cutaneous PTCLs, mycosis fungoides, Sezary syndrome and
chronic lymphoproliferative disorder of NK cells. Among 517 patients with
mature T-cell lymphoma, 228 patients were included in the analysis
(Figure 1). This study was approved by the institutional review board of
Association for the Accreditation of Human Research Protection Program
approved center. The study was carried out in accordance with the precepts
of the Declaration of Helsinki.
diagnosis of CNS disease
CNS disease was deﬁned as any evidence of CNS involvement any time after
initial diagnosis. CNS disease was divided into two categories; an isolated
CNS involvement without evidence of systemic residual disease and
combined involvement of CNS with other systemic involvement.
The types of CNS disease consisted of parenchymal metastases and
leptomeningeal invasion. Parenchymal disease was diagnosed by magnetic
resonance imaging (MRI) or a brain computed tomography scan.
Leptomeningeal involvement was diagnosed on the basis of cerebrospinal
ﬂuid (CSF) cytology and three diagnostic criteria were applied. These
criteria were (i) presence of malignant lymphomatous cells in the CSF, (ii)
presence of suspicious cells with increased protein level in the CSF or (iii)
presence of suspicious cells with suggestive ﬁndings of leptomeningeal
seeding on MRI. The deﬁnition of suspicious cells was lymphocytes with an
atypical morphology.
clinical parameters
We retrospectively collected clinical parameters from patients’ medical
records, including age, sex, ﬁnal pathologic diagnosis, date and the regimen
of the ﬁrst treatment, date of last visit or expiration, performance status
(PS), Ann Arbor stage, presence of extranodal involvement, bone marrow
Table 2. Baseline characteristics of patients with PTCLs according to
CNS involvement
Without CNS
involvement (%)
With CNS
involvement (%)
Number of cases (total N = 228) 208 20
Sex
Male 133 (63.9) 10 (50.0)
Female 75 (36.1) 10 (50.0)
Age (years)
£50 92 (44.2) 9 (45.0)
>50 116 (55.8) 11 (55.0)
ECOG PS
PS 0–1 148 (71.2) 11 (55.0)
PS 2–4 60 (28.8) 9 (45.0)
B symptom
Present 93 (45.1) 7 (35.0)
Absent 113 (54.9) 13 (65.0)
Serum LDH
£Upper normal limit 82 (39.6) 2 (10.0)
>Upper normal limit 125 (60.4) 18 (90.0)
Number of extranodal site involvement
0–1 131 (63.3) 10 (50.0)
2 or more 76 (36.7) 10 (50.0)
Visceral organ involvement
Present 71 (34.1) 11 (55.0)
Absent 137 (65.9) 9 (45.0)
Bone marrow involvement
Present 81 (39.1) 6 (30.0)
Absent 126 (60.9) 14 (70.0)
Sinonasal area involvement
Present 25 (12.0) 6 (30.0)
Absent 183 (88.0) 14 (70.0)
Ann Arbour stage
I/II 46 (22.1) 3 (15.0)
III/IV 162 (77.9) 17 (85.0)
International prognostic index risk
Low/low intermediate 115 (55.3) 13 (65.0)
High/high intermediate 93 (44.7) 7 (35.0)
PIT group
1/2 99 (47.6) 13 (65.0)
3/4 109 (52.4) 7 (35.0)
Histologic subtype
PTCL-unspeciﬁed 119 11 (8.5)
a
ALCL 27 5 (15.6)
a
AITL 49 3 (5.8)
a
EATL 7 1 (12.5)
a
HSTL 6 0 (0.0)
a
aAmong the same histologic subtype.
PTCL, peripheral T-cell lymphoma; CNS, central nervous system; ECOG,
Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate
dehydrogenase; PIT, prognostic index for PTCL-NOS; ALCL, anaplastic
large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATL,
enteropathy-associated T-cell lymphoma; HSTL, hepatosplenic T-cell
lymphoma.
Table 3. Clinical manifestations of CNS disease
Histologic subtypes Total PTCL-NOS ALCL AITL EATL
Disease relationship between CNS and whole-body system
Isolated CNS relapse 2 2 0 0 0
With systemic involvement 18 9 5 3 1
The type of CNS disease
Leptomeningeal seeding 14 7 4 2 1
Parenchymal metastasis 5 3 1 1 0
Combined 1 1 0 0 0
CNS, central nervous system; PTCL-NOS, peripheral T-cell lymphoma, not
otherwise speciﬁed; ALCL, anaplastic large cell lymphoma; AITL,
angioimmunoblastic T-cell lymphoma; EATL, enteropathy-associated T-
cell lymphoma.
original article Annals of Oncology
1638 | Yi et al. Volume 22| No. 7| July 2011Table 4. The clinical features of individual patients with CNS relapse
Sex Age Histology Stage Site of involvement IPI risk First-line therapeutic
regimen
Disease status at the
presentation of CNS
disease
Time to CNS
event (months)
Pattern Therapy directed to
CNS disease
CNS
response
Survival after CNS
disease (months)
CNS involvement without systemic residual disease
M 44 PTCL-NOS IVB Testis HI CHOP#6 CR after CHOP 32.13 P/I RT/ASCT CR 13.3
M 43 PTCL-NOS IIIB Temporal bone LI CHOP#6 CR after CHOP 6.37 P/I RT CR 100.5
M 43 PTCL-NOS IVB Nasal cavity, testis LI CHOP#3 CR after ASCT 9.00 L/S IT PD 1.0
M 56 PTCL-NOS IIIA Infraauricular mass LI CHOP#6 CR after ASCT 29.60 L/S IT/CT CR 12.1+
F 24 PTCL-NOS IVA Ovary, lung, thyroid HI CHOP#3 CR after ASCT 12.40 L&P/S RT PR 3.9
F 57 EATL IIIA Colon LI CHOP#4 CR after salvage
therapy
7.7 L/S CT NE 0.3
M 59 ALCL, ALK2 IIB Nasal cavity L CHOP#2 CR after CHOP 3.53 P/S Not done NE 2.8
CNS involvement with systemic residual disease
M 55 AITL IVB Omentum, liver, BM HI CHOP#2/IT Initial diagnosis 0 L/S IT/CT CR 4.6
M 54 PTCL-NOS IVA Colon, ileum, BM HI CHOP#2/IT Initial diagnosis 0 L/S IT/CT CR 3.1
F 52 AITL IIIB Peritoneal, inguinal
LN
LI CHOP#6 PD after salvage CT 71.23 L/S CT NE 2.7
F 69 ALCL IIB Epiglottis LI CHOP#4 PD after salvage CT 5.73 L/S RT PD 0.07
F 50 AITL IIIA Infraauricular mass LI CHOP#1 During salvage CT 2.90 P/S RT/IT/CT PD 3.6
F 59 PTCL-NOS IVB BM, neck LN LI CHOP#1 During salvage CT 1.43 P/S RT/CT/ASCT CR 100.1
M 38 ALCL, ALK+ IVA Small bowel, lung LI CHOP#3 During salvage CT 8.03 L/S IT/RT CR 2.5
F 57 PTCL-NOS IIIA Stomach LI CHOP#5 PD after salvage CT 6.97 L/S RT PD 0.3
F 31 ALCL, ALK+ IVB Skin, liver, BM H CHOP#2 During ﬁrst-line CT 1.03 L/S Not done NE 0.2
F 59 ALCL, ALK2 IVB Nasopharynx, lung HI CHOP#1 During ﬁrst-line CT 2.17 L/S IT NE 0.3
M 31 PTCL-NOS IVB Skin, liver H CHOP#2 During salvage CT 1.90 L/S Not done NE 0.5
M 60 PTCL-NOS IVB Jejunum, rib H Bortezomib-CHOP#1 During ﬁrst-line CT 0.6 L/S IT/CT CR 6.7+
F 21 PTCL-NOS IVB Skin, BM LI CHOP#3 During ﬁrst-line CT 1.97 L/S IT/ASCT CR 4.6
PTCL-NOS, peripheral T-cell lymphoma, not otherwise speciﬁed; EATL, enteropathy-associated T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma; kinase; AITL,
angioimmunoblastic T-cell lymphoma; IPI, international prognostic index; HI, high intermediate risk group; LI, low intermediate risk group; L, low risk group; H, high risk group; CHOP, combination
chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone; CR, complete remission; PR, partial remission; PD, progressive disease; NE, not evaluated; CT, chemotherapy; RT, whole-brain
radiation therapy; IT, intrathecal chemotherapy; ASCT, autologous stem cell transplantation; P, parenchymal disease; L, leptomeningeal disease; I, isolated central nervous system (CNS) involvement; S,
combined with systemic progression; BM, bone marrow; LN, lymph node.
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9involvement, paranasal sinus involvement or B symptoms and serum level
of LDH. We calculated the prognostic models, international prognostic
index (IPI) and prognostic index for PTCL-NOS (PIT).
statistical analysis
Time to CNS disease was deﬁned as the time from the beginning of therapy
to the diagnosis of CNS disease and was estimated from Kaplan–Meier
curves. We carried out a log-rank test for univariate analysis of the other
clinical parameters. A two-sided P value of <0.05 was considered signiﬁcant.
The Cox proportional hazards regression model was used in multivariate
analysis to compare the factors proven to be statistically signiﬁcant or to
demonstrate a trend in the univariate analysis.
results
patient characteristics
The 228 patients had a median age 53 years (range 16–88), and
143 (62.7%) patients were male. With regard to histologic
subtypes, 130 (57.0%) patients had PTCL-NOS, 52 (22.8%)
had AITL, 32 (14.0%) had ALCL, 8 (3.5%) had EATL and 6
(2.6%) had HSTL. Among patients with ALCL, 11 were positive
for anaplastic lymphoma kinase (ALK), 12 were negative for
ALK and 9 were not examined for ALK status. The clinical
parameters according to histologic subtype are summarized in
Table 1. As for ﬁrst-line treatment, 204 patients (89.5%) had
received combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) or CHOP-
like therapy, 14 patients (6.1%) had received chemotherapy
other than CHOP-like regimen and 10 patients (4.4%) had not
received any kinds of deﬁnitive therapy. None of the patients
had received CNS prophylaxis. Two patients who initially had
CNS involvement at the time of diagnosis started IT MTX with
ﬁst-line systemic chemotherapy (CHOP).
clinical features of CNS disease
CNS involvement was observed in 20 out of 228 patients
(8.77 %) during a median follow-up period of 13.9 months
(range 0.03–159.43). The baseline characteristics of patients
with PTCLs according to CNS involvement are described in
Table 2. Among the histologic subtypes, ALCL had the highest
proportion of CNS disease (5/32, 15.6%). Two patients were
positive for ALK, two were negative and one was not examined
for ALK status. None of the patients with HSTL (0/8, 0%) and
a relatively small portion of patients with AITL (3/52, 5.8%)
had CNS disease. However, there was no statistically signiﬁcant
difference among the histologic subgroups (P = 0.348).
The clinical manifestations of CNS disease are summarized in
Table 3. Fourteen (70.0%) patients had leptomeningeal
involvement, ﬁve (25.0%) had parenchymal metastasis and one
(5.0%) had both. Two (10.0%) patients had isolated CNS
involvement and 18 (90.0%) had CNS disease along with
another systemic disease. Both patients with isolated CNS
involvement had parenchymal metastasis and among the 18
patients with combined CNS and systemic involvement, 14 had
leptomeningeal seeding, 3 had parenchymal metastasis and 1
had both types of involvement.
The median time to CNS disease was 6.05 months (range
0.0–71.2). The clinical features of individual patients with CNS
disease and their courses are summarized in Table 4. Two
patients had CNS involvement at the time of initial diagnosis, 7
patients had recurring disease of the CNS after complete
remission after systemic chemotherapy or autologous stem cell
transplantation and 11 patients had CNS disease developed
during the ﬁrst-line or salvage chemotherapy with residual
systemic disease.
Survival of the patients with CNS involvement was
signiﬁcantly shorter than that of patients without CNS
involvement (P = 0.009), with median overall survival of 7.60
months [95% conﬁdence interval (CI) 4.92–10.28] versus 27.43
months (95% CI of 0.00–57.38), respectively (Figure 2).
Two patients died from progression of CNS disease, 11 patients
died of systemic progression and 7 patients were lost during
follow-up.
Figure 2. Overall survival according to central nervous system involvement.
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An increased risk for CNS involvement was associated with
increased LDH level [P = 0.015, relative risk (RR) 7.282, 95%
CI 1.472–36.033] and involvement of the paranasal sinus (P =
0.029, RR 3.514, 95% CI 1.134–10.893) in univariate analysis.
Risk factors of CNS involvement in B-cell lymphoma, such as
bone marrow involvement, advanced age or Ann Arbor stage
and extranodal involvement, did not increase the risk for CNS
involvement in cases of PTCL (Table 5).
In multivariate analysis, both the increased LDH level [P =
0.011, hazard ratio (HR) = 6.716, 95% CI 1.548–29.131] and
involvement of the paranasal sinus (P = 0.008, HR 3.784, 95%
CI 1.420–10.083) were predictive factors for CNS disease.
Comparing the patients with zero, one or two risk factors, the
incidences of CNS involvement were signiﬁcantly different
among the groups (Figure 3). One out of 75 (1.3%) patients
without any risk factor, 14 out of 132 (10.6%) patients with one
risk factor and 5 out of 21 (23.8%) patients with both risk
factors had CNS disease (P = 0.010).
discussion
The risk of CNS involvement is 30–50% in patients with
aggressive lymphomas such as lymphoblastic lymphoma/
leukemia or Burkitt’s lymphoma [17–19], and 5–10% in
patients with diffuse large B-cell lymphoma [4].
In cases of PTCLs, there have been few reports of the
incidence of CNS involvement, risk factors or prognostic role
on overall survival. Kim et al. reported that 5.76% of secondary
CNS involvement in patients with extranodal NK/T cell
lymphoma, nasal type and group III/IV NKPI [20] has
statistical power to predict secondary CNS disease.
In our study, 20 out of 228 patients (8.77%) had CNS
disease. Patients with ALCL had the highest incidence (5/32,
15.6%), and among 32 patients with ALCL, ALK status was
examined in 23 patients. Twelve patients were ALK negative
and 11 were ALK positive. Although ALK-positive ALCL is
known to have a better prognosis, there was no difference in
CNS involvement between the ALK-positive and ALK-negative
groups (P = 0.924).
Patients with AITL had the least CNS involvement (3/52,
5.8%). In many cases, patients with AITL have advanced age, B
symptoms, poor PS, elevated LDH and advanced stage, all of
which are known to adversely affect the prognoses of the
patients [21, 22]. However, according to our study, CNS
involvement seems to be relatively rare in AITL. For cases of
HSTL, which is also known to have an aggressive clinical course
such as visceral organ/extranodal involvement or pancytopenia,
there was no CNS involvement. As our study analyzed only six
patients with HSTL, a larger clinical study is necessary to
determine the CNS involvement with HSTL.
IPI and PIT have been applied to various kinds of PTCLs,
and many have a reported prognostic value [3, 21, 23, 24]. In
our study, however, neither IPI nor PIT was related to CNS
disease, which may be the result of a lack of predictive roles of
age, advanced stage, extranodal involvement, PS or bone
marrow involvement. The known incidence of CNS
involvement and risk factors according to histologic subtypes
are summarized in Table 6.
The median time to ﬁrst CNS involvement in our study was
6.05 months (range 0.0–71.2 months). Using the results of
previous reports, this is somewhat shorter than that of the B-
cell lymphomas (5–12 months [4]) and is similar to that of
extranodal NK/T cell lymphoma, nasal type (6.03 months
[20]).
Seven patients had CNS disease that relapsed without
evidence of systemic residual disease. The longest disease-free
interval between systemic remission and CNS relapse was 32.13
months, where the primary disease was PTCL-NOS in testis.
Another patient with testis involvement of PTCL-NOS had
CNS relapse after 9 months of complete remittance. Of 228
patients, three had testicular involvement and two had CNS
disease. This suggests that the testis could also be a sanctuary
Table 5. Univariate analysis for CNS involvement in patients with
PTCLs
RR 95% CI P value
Sex
Male
Female 1.773 0.706–4.455 0.223
Age (years)
£50
>50 0.969 0.385–2.438 0.947
Serum LDH
£Upper normal limit
>Upper normal limit 5.904 1.334–26.123 0.019
B symptoms
Absent
Present 1.528 0.586–3.988 0.386
Ann Arbor stage
I/II
III/IV 1.609 0.452–5.731 0.463
Extranodal involvement
0–1
2 or more 1.724 0.686–4.329 0.247
Visceral organ involvement
Absent
Present 2.358 0.934–5.956 0.069
PS
0–1
2–4 2.018 0.796–5.118 0.139
Paranasal sinus involvement
Absent
Present 3.137 1.105–8.908 0.032
Bone marrow involvement
Absent
Present 0.667 0.246–1.805 0.425
IPI
I/II
III/IV 0.666 0.255–1.737 0.406
PIT
III/IV
I/II 0.489 0.188–1.275 0.143
CNS, central nervous system; PTCL, peripheral T-cell lymphoma; RR,
relative risk; CI, conﬁdence interval; LDH, lactate dehydrogenase; PS,
performance status; IPI, international prognostic index; PIT, prognostic
index for PTCL-NOS.
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considered a high-risk site for CNS relapse in PTCLs, as in the
case of B-cell lymphomas. A larger analysis is required to
further analyze this as a factor.
The median survival duration of patients with CNS disease
was signiﬁcantly shorter than that of patients without CNS
disease. Among 13 patients with CNS disease whose clinical
courses were followed up, 11 patients died of systemic
progression and only two died of CNS progression. CNS
relapse might be a manifestation of systemic progression, or
untreated malignant lymphocytes could remain in the brain
parenchymal tissue or CSF.
Fourteen out of 132 (10.6 %) patients with either risk factor
(elevated LDH level, paranasal sinus involvement) and 5 out of
21 (23.8%) patients with both risk factors had CNS
involvement. This implies that screening and follow-up
examinations for CNS involvement should be considered in
patients with any risk factor, although there is no consensus on
efﬁcacy, what therapeutic agents or methods should be used for
the treatment [4]. Further large-scaled analysis is necessary on
this issue.
In summary, elevated serum LDH level and involvement of
the paranasal sinus are risk factors for CNS involvement in
patients with PTCLs. CNS prophylaxis might be considered for
Table 6. Published data of incidence and risk factors for CNS disease according to histologic subtype
Diffuse large B-cell lymphoma
a Extranodal NK/T-cell lymphoma
b PTCL
c
Incidence 5–10% 5.76% 8.77%
Risk factors Advanced age High IPI score
Two or more extranodal
involvement Paranasal
sinus involvement Bone
marrow involvement
Testicular involvement
III/IV NKPI group
d Presence
of B symptoms Advanced
stage Elevated LDH level
Regional lymph nodes
involvement
Elevated LDH level Paranasal
sinus involvement
aBlood Rev 2006; 20: 319–332.
bAnn Oncol 2010; 21 (5): 1058–1063.
cThis study.
dJ Clin Oncol 2006; 24: 612–618.
CNS, central nervous system; NK, natural killer; PTCL, peripheral T-cell lymphoma; IPI, international prognostic index; NKPI, NK/T-cell lymphoma
prognostic index; LDH, lactate dehydrogenase.
Figure 3. Cumulative incidence of central nervous system relapse according to number of the risk factors.
original article Annals of Oncology
1642 | Yi et al. Volume 22| No. 7| July 2011patients with any risk factors although it is not clear what the
treatment option should be.
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